In patients who have undergone PCI, guidelines suggest 6–12 months of dual antiplatelet therapy (DAPT), typically with aspirin plus a P2Y12 inhibitor such as clopidogrel. After the initial 6–12 month period, lifetime aspirin monotherapy is recommended. Prof. Hyo-Soo Kim (Seoul National University Hospital, South Korea) and colleagues aimed to explore whether an alternative monotherapy could achieve superior clinical outcomes compared with aspirin.
The primary endpoint was a composite of all-cause death, acute coronary syndrome including non-fatal MI, stroke, the need for revascularisation while under antiplatelet therapy, or Bleeding Academic Research Consortium (BARC) type ≥3 bleeds. At 2 years, 152 (5.7%) primary endpoint events had occurred in the clopidogrel group compared with 207 (7.7%) in the aspirin group (HR 0.73; 95% CI 0.59–0.70; P=0.0035).
These results demonstrated that clopidogrel monotherapy was associated with better net outcomes, driven by bleeding, to aspirin monotherapy following an event-free 6–18 months period of DAPT after PCI with DES.
The researchers acknowledged several limitations of this trial. It was open-label and conducted only in South Korea. East Asians tend to have a higher prevalence of loss-of-function mutations of the CYP2C19 gene, yet they tend to have lower rates of thrombosis and higher rates of bleeding events following PCI (the “East Asian paradox”) [1,3]. Furthermore, most of the enrolled patients had followed a DAPT regimen for about 1 year; thus, results may not be generalisable to those who have been on DAPT for a shorter period. The investigators have launched the HOST-EXAM extended study, which will continue to follow these participants for a median of 10 years [1].
- Kim HS. Aspirin Vs. Clopidogrel During Chronic Maintenance Monotherapy After Percutaneous Coronary Intervention: The Host Exam Randomised Controlled Trial. Abstract 407-12, ACC 2021 Scientific Session, 15–17 May.
- Koo BK, et al. Lancet. 2021;May 16. DOI: 1016/S0140-6736(21)01063-1.
- Jeong YH. Curr Cardiol Rep. 2014;16(5):485.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Sacubitril/valsartan does not reduce NT-proBNP versus valsartan alone in HFrEF Next Article
Prasugrel better than ticagrelor in ACS patients undergoing PCI »
« Sacubitril/valsartan does not reduce NT-proBNP versus valsartan alone in HFrEF Next Article
Prasugrel better than ticagrelor in ACS patients undergoing PCI »
Table of Contents: ACC 2021
Featured articles
Electrophysiology
Favourable outcomes with transcatheter atrial appendage occlusion
Etripamil nasal spray significantly improves PSVT-related symptoms
Ablation-based rhythm control as effective as rate control in AF and HF
Finerenone reduces the risk of AF onset in patients with CKD and diabetes
Heart Failure and Cardiomyopathy
PARADISE-MI: Sacubitril/valsartan not superior to ramipril in reducing HF events
Older adults with heart failure benefit from rehabilitation programme
Quality improvement intervention fails to improve care for patients with heart failure
Sacubitril/valsartan does not reduce NT-proBNP versus valsartan alone in HFrEF
Novel use of ivabradine in reversible cardiomyopathy
Mavacamten significantly improves QoL of patients with hypertrophic cardiomyopathy
Interventional and Structural Cardiology
Men and women benefit equally from early aspirin withdrawal following PCI
Similar outcomes with fractional flow reserve and angiography-guided revascularisation
TALOS-AMI: Exploring outcomes after switching to clopidogrel versus ticagrelor at 1 month from MI
Clopidogrel monotherapy associated with better net outcomes relative to aspirin monotherapy 6-18 months after PCI
Ischaemic Heart Disease
No difference in ischaemic risk or bleeding with low vs high-dose aspirin for secondary prevention: Lessons and questions from the ADAPTABLE trial
Rivaroxaban reduces total ischaemic events after peripheral artery revascularisation
Moderate hypothermia not superior to mild hypothermia following out-of-hospital cardiac arrest
Better outcomes with invasive strategy if anatomic complete revascularisation is possible
Prevention and Health Promotion
STRENGTH trial fails to demonstrate cardioprotective effect of omega-3 fatty acids
Evinacumab lowers triglyceride levels in severe hypertriglyceridaemia
Health equity and the role of the cardiologist: 7 priorities to consider
COVID-19
Dapagliflozin fails to show a significant protective effect in COVID-19
Therapeutic anticoagulation not superior to prophylactic anticoagulation in COVID-19
Atorvastatin does not reduce mortality in COVID-19
Valvular Heart Disease
Apixaban outcomes similar to current standard of care following TAVR
Preliminary results encouraging for EVOQUE tricuspid valve replacement
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com